恆指跌幅擴大至270點 創科、舜宇及銀娛挫逾半成 招行創近兩年低
恆指跌幅擴大至270點或近1.3%,報19,386,成交582億元。
藍籌股普遍跌逾1%-3%;出口股創科(00669.HK)及手機股舜宇(02382.HK)跌幅更擴至逾半成,報95.35元及106.4元;銀娛(00027.HK)跌幅擴至5.6%報43.05元。此外,金融股以藍籌招行(03968.HK)沽壓較大,股價續跌3.2%報38.8元,創近兩年低。
然而,安踏(02020.HK)中期少賺6.6%但增派息至62港仙,該股午後曾抽升8.3%高見95.8元,現報90.5元,升2.3%;績後獲多間大行調高目標價的新奧能源(02688.HK)扭四連挫,股價由逾三個月低位升逾3%報106.9元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.